nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—FGF1—breast cancer	0.441	0.648	CbGaD
Amlexanox—PDE4D—breast cancer	0.24	0.352	CbGaD
Amlexanox—IL3—embryo—breast cancer	0.00602	0.0831	CbGeAlD
Amlexanox—IL3—bone marrow—breast cancer	0.00344	0.0475	CbGeAlD
Amlexanox—IL3—endocrine gland—breast cancer	0.00309	0.0426	CbGeAlD
Amlexanox—FGF1—mammary gland—breast cancer	0.00258	0.0356	CbGeAlD
Amlexanox—PDE4A—mammary gland—breast cancer	0.00244	0.0337	CbGeAlD
Amlexanox—S100A13—epithelium—breast cancer	0.00233	0.0322	CbGeAlD
Amlexanox—S100A12—epithelium—breast cancer	0.0023	0.0317	CbGeAlD
Amlexanox—S100A13—skin of body—breast cancer	0.00222	0.0306	CbGeAlD
Amlexanox—IL3—lymph node—breast cancer	0.00213	0.0295	CbGeAlD
Amlexanox—S100A13—adipose tissue—breast cancer	0.00188	0.026	CbGeAlD
Amlexanox—S100A12—pituitary gland—breast cancer	0.00187	0.0258	CbGeAlD
Amlexanox—S100A12—adipose tissue—breast cancer	0.00186	0.0257	CbGeAlD
Amlexanox—FGF1—embryo—breast cancer	0.00176	0.0243	CbGeAlD
Amlexanox—S100A13—female reproductive system—breast cancer	0.00173	0.0239	CbGeAlD
Amlexanox—S100A13—adrenal gland—breast cancer	0.00169	0.0233	CbGeAlD
Amlexanox—S100A12—adrenal gland—breast cancer	0.00167	0.023	CbGeAlD
Amlexanox—S100A12—bone marrow—breast cancer	0.00161	0.0223	CbGeAlD
Amlexanox—S100A13—female gonad—breast cancer	0.00158	0.0217	CbGeAlD
Amlexanox—S100A12—female gonad—breast cancer	0.00155	0.0215	CbGeAlD
Amlexanox—S100A13—endocrine gland—breast cancer	0.00146	0.0202	CbGeAlD
Amlexanox—S100A12—endocrine gland—breast cancer	0.00145	0.02	CbGeAlD
Amlexanox—FGF1—epithelium—breast cancer	0.00143	0.0198	CbGeAlD
Amlexanox—Liver function test abnormal—Toremifene—breast cancer	0.00139	0.0189	CcSEcCtD
Amlexanox—FGF1—skin of body—breast cancer	0.00136	0.0188	CbGeAlD
Amlexanox—Stomatitis—Lapatinib—breast cancer	0.00125	0.017	CcSEcCtD
Amlexanox—PDE4D—adipose tissue—breast cancer	0.00124	0.0171	CbGeAlD
Amlexanox—PDE4B—nipple—breast cancer	0.0012	0.0166	CbGeAlD
Amlexanox—FGF1—pituitary gland—breast cancer	0.00116	0.0161	CbGeAlD
Amlexanox—FGF1—adipose tissue—breast cancer	0.00116	0.016	CbGeAlD
Amlexanox—Mouth ulceration—Chlorambucil—breast cancer	0.00113	0.0154	CcSEcCtD
Amlexanox—PDE4D—adrenal gland—breast cancer	0.00111	0.0154	CbGeAlD
Amlexanox—PDE4A—adipose tissue—breast cancer	0.0011	0.0151	CbGeAlD
Amlexanox—Liver function test abnormal—Anastrozole—breast cancer	0.00109	0.0148	CcSEcCtD
Amlexanox—FGF1—female reproductive system—breast cancer	0.00107	0.0147	CbGeAlD
Amlexanox—FGF1—adrenal gland—breast cancer	0.00104	0.0144	CbGeAlD
Amlexanox—PDE4D—female gonad—breast cancer	0.00104	0.0143	CbGeAlD
Amlexanox—Paraesthesia—Fluoxymesterone—breast cancer	0.00103	0.0141	CcSEcCtD
Amlexanox—S100A13—lymph node—breast cancer	0.00101	0.014	CbGeAlD
Amlexanox—S100A12—lymph node—breast cancer	0.000999	0.0138	CbGeAlD
Amlexanox—PDE4A—adrenal gland—breast cancer	0.000984	0.0136	CbGeAlD
Amlexanox—Mouth ulceration—Melphalan—breast cancer	0.000982	0.0134	CcSEcCtD
Amlexanox—FGF1—female gonad—breast cancer	0.00097	0.0134	CbGeAlD
Amlexanox—Stomatitis—Ixabepilone—breast cancer	0.000939	0.0128	CcSEcCtD
Amlexanox—PDE4A—female gonad—breast cancer	0.000917	0.0127	CbGeAlD
Amlexanox—FGF1—endocrine gland—breast cancer	0.000902	0.0125	CbGeAlD
Amlexanox—Throat sore—Paclitaxel—breast cancer	0.000886	0.0121	CcSEcCtD
Amlexanox—Stomatitis—Letrozole—breast cancer	0.000884	0.0121	CcSEcCtD
Amlexanox—Oropharyngeal discomfort—Paclitaxel—breast cancer	0.000878	0.012	CcSEcCtD
Amlexanox—Stomatitis—Idarubicin—breast cancer	0.000839	0.0114	CcSEcCtD
Amlexanox—Nervous system disorder—Lapatinib—breast cancer	0.000799	0.0109	CcSEcCtD
Amlexanox—Aphthous stomatitis—Epirubicin—breast cancer	0.000778	0.0106	CcSEcCtD
Amlexanox—Throat sore—Docetaxel—breast cancer	0.000751	0.0102	CcSEcCtD
Amlexanox—Oropharyngeal discomfort—Docetaxel—breast cancer	0.000744	0.0101	CcSEcCtD
Amlexanox—Liver function test abnormal—Tamoxifen—breast cancer	0.000744	0.0101	CcSEcCtD
Amlexanox—Pain—Carboplatin—breast cancer	0.000739	0.0101	CcSEcCtD
Amlexanox—Nervous system disorder—Fulvestrant—breast cancer	0.000735	0.01	CcSEcCtD
Amlexanox—Liver function test abnormal—Melphalan—breast cancer	0.000728	0.00993	CcSEcCtD
Amlexanox—Throat sore—Capecitabine—breast cancer	0.000727	0.00991	CcSEcCtD
Amlexanox—PDE4B—endometrium—breast cancer	0.000726	0.01	CbGeAlD
Amlexanox—Nervous system disorder—Toremifene—breast cancer	0.000725	0.00989	CcSEcCtD
Amlexanox—Oropharyngeal discomfort—Capecitabine—breast cancer	0.00072	0.00982	CcSEcCtD
Amlexanox—Aphthous stomatitis—Doxorubicin—breast cancer	0.00072	0.00982	CcSEcCtD
Amlexanox—Headache—Fluoxymesterone—breast cancer	0.000719	0.00981	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Lapatinib—breast cancer	0.000704	0.00959	CcSEcCtD
Amlexanox—Oropharyngeal pain—Paclitaxel—breast cancer	0.000702	0.00957	CcSEcCtD
Amlexanox—Nausea—Fluoxymesterone—breast cancer	0.000682	0.0093	CcSEcCtD
Amlexanox—Stomatitis—Chlorambucil—breast cancer	0.00068	0.00927	CcSEcCtD
Amlexanox—Paraesthesia—Fulvestrant—breast cancer	0.000673	0.00918	CcSEcCtD
Amlexanox—PDE4D—lymph node—breast cancer	0.000667	0.0092	CbGeAlD
Amlexanox—PDE4B—pituitary gland—breast cancer	0.000657	0.00907	CbGeAlD
Amlexanox—PDE4B—adipose tissue—breast cancer	0.000654	0.00903	CbGeAlD
Amlexanox—Gastrointestinal disorder—Fulvestrant—breast cancer	0.000647	0.00882	CcSEcCtD
Amlexanox—Pain—Fulvestrant—breast cancer	0.000641	0.00874	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Toremifene—breast cancer	0.000639	0.00871	CcSEcCtD
Amlexanox—Nervous system disorder—Exemestane—breast cancer	0.000638	0.00871	CcSEcCtD
Amlexanox—Pain—Toremifene—breast cancer	0.000633	0.00863	CcSEcCtD
Amlexanox—FGF1—lymph node—breast cancer	0.000623	0.00861	CbGeAlD
Amlexanox—Nervous system disorder—Ixabepilone—breast cancer	0.000602	0.00821	CcSEcCtD
Amlexanox—PDE4B—female reproductive system—breast cancer	0.000601	0.0083	CbGeAlD
Amlexanox—Oropharyngeal pain—Docetaxel—breast cancer	0.000595	0.00811	CcSEcCtD
Amlexanox—Stomatitis—Melphalan—breast cancer	0.000592	0.00808	CcSEcCtD
Amlexanox—PDE4A—lymph node—breast cancer	0.00059	0.00814	CbGeAlD
Amlexanox—PDE4B—adrenal gland—breast cancer	0.000587	0.0081	CbGeAlD
Amlexanox—Paraesthesia—Exemestane—breast cancer	0.000585	0.00797	CcSEcCtD
Amlexanox—Mouth ulceration—Paclitaxel—breast cancer	0.000577	0.00787	CcSEcCtD
Amlexanox—Oropharyngeal pain—Capecitabine—breast cancer	0.000576	0.00786	CcSEcCtD
Amlexanox—PDE4B—bone marrow—breast cancer	0.000568	0.00784	CbGeAlD
Amlexanox—Nervous system disorder—Letrozole—breast cancer	0.000567	0.00774	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Exemestane—breast cancer	0.000562	0.00766	CcSEcCtD
Amlexanox—Pain—Exemestane—breast cancer	0.000557	0.00759	CcSEcCtD
Amlexanox—Paraesthesia—Ixabepilone—breast cancer	0.000552	0.00752	CcSEcCtD
Amlexanox—PDE4B—female gonad—breast cancer	0.000547	0.00755	CbGeAlD
Amlexanox—Nervous system disorder—Raloxifene—breast cancer	0.000538	0.00734	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Ixabepilone—breast cancer	0.00053	0.00723	CcSEcCtD
Amlexanox—Pain—Ixabepilone—breast cancer	0.000525	0.00716	CcSEcCtD
Amlexanox—Paraesthesia—Anastrozole—breast cancer	0.000519	0.00708	CcSEcCtD
Amlexanox—Paraesthesia—Letrozole—breast cancer	0.000519	0.00708	CcSEcCtD
Amlexanox—Stomatitis—Vinorelbine—breast cancer	0.000518	0.00706	CcSEcCtD
Amlexanox—Liver function test abnormal—Gemcitabine—breast cancer	0.000511	0.00697	CcSEcCtD
Amlexanox—Headache—Lapatinib—breast cancer	0.000511	0.00696	CcSEcCtD
Amlexanox—PDE4B—endocrine gland—breast cancer	0.000509	0.00702	CbGeAlD
Amlexanox—Gastrointestinal disorder—Anastrozole—breast cancer	0.000499	0.00681	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Letrozole—breast cancer	0.000499	0.00681	CcSEcCtD
Amlexanox—Pain—Letrozole—breast cancer	0.000495	0.00675	CcSEcCtD
Amlexanox—Pain—Anastrozole—breast cancer	0.000495	0.00675	CcSEcCtD
Amlexanox—Stomatitis—Thiotepa—breast cancer	0.000494	0.00674	CcSEcCtD
Amlexanox—Nausea—Lapatinib—breast cancer	0.000484	0.0066	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Raloxifene—breast cancer	0.000474	0.00646	CcSEcCtD
Amlexanox—Mouth ulceration—Capecitabine—breast cancer	0.000474	0.00646	CcSEcCtD
Amlexanox—Headache—Fulvestrant—breast cancer	0.00047	0.0064	CcSEcCtD
Amlexanox—Pain—Raloxifene—breast cancer	0.00047	0.0064	CcSEcCtD
Amlexanox—Headache—Toremifene—breast cancer	0.000463	0.00632	CcSEcCtD
Amlexanox—Nausea—Fulvestrant—breast cancer	0.000445	0.00607	CcSEcCtD
Amlexanox—Nausea—Toremifene—breast cancer	0.000439	0.00599	CcSEcCtD
Amlexanox—Liver function test abnormal—Paclitaxel—breast cancer	0.000428	0.00583	CcSEcCtD
Amlexanox—Stomatitis—Irinotecan—breast cancer	0.000427	0.00582	CcSEcCtD
Amlexanox—Stomatitis—Mitoxantrone—breast cancer	0.000427	0.00582	CcSEcCtD
Amlexanox—Stomatitis—Gemcitabine—breast cancer	0.000416	0.00567	CcSEcCtD
Amlexanox—Stomatitis—Fluorouracil—breast cancer	0.000409	0.00557	CcSEcCtD
Amlexanox—Headache—Exemestane—breast cancer	0.000408	0.00556	CcSEcCtD
Amlexanox—Nausea—Exemestane—breast cancer	0.000387	0.00527	CcSEcCtD
Amlexanox—Headache—Ixabepilone—breast cancer	0.000385	0.00525	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Chlorambucil—breast cancer	0.000384	0.00523	CcSEcCtD
Amlexanox—Pain—Chlorambucil—breast cancer	0.00038	0.00519	CcSEcCtD
Amlexanox—Nervous system disorder—Goserelin—breast cancer	0.000371	0.00506	CcSEcCtD
Amlexanox—Paraesthesia—Vinblastine—breast cancer	0.000366	0.00499	CcSEcCtD
Amlexanox—Nausea—Ixabepilone—breast cancer	0.000365	0.00498	CcSEcCtD
Amlexanox—Liver function test abnormal—Docetaxel—breast cancer	0.000363	0.00495	CcSEcCtD
Amlexanox—Headache—Anastrozole—breast cancer	0.000362	0.00494	CcSEcCtD
Amlexanox—Headache—Letrozole—breast cancer	0.000362	0.00494	CcSEcCtD
Amlexanox—Paraesthesia—Tamoxifen—breast cancer	0.000355	0.00485	CcSEcCtD
Amlexanox—Mouth ulceration—Methotrexate—breast cancer	0.000353	0.00481	CcSEcCtD
Amlexanox—PDE4B—lymph node—breast cancer	0.000352	0.00486	CbGeAlD
Amlexanox—Liver function test abnormal—Capecitabine—breast cancer	0.000351	0.00479	CcSEcCtD
Amlexanox—Pain—Vinblastine—breast cancer	0.000348	0.00475	CcSEcCtD
Amlexanox—Stomatitis—Paclitaxel—breast cancer	0.000348	0.00475	CcSEcCtD
Amlexanox—Paraesthesia—Melphalan—breast cancer	0.000348	0.00475	CcSEcCtD
Amlexanox—Headache—Idarubicin—breast cancer	0.000344	0.00469	CcSEcCtD
Amlexanox—Headache—Raloxifene—breast cancer	0.000344	0.00469	CcSEcCtD
Amlexanox—Nausea—Anastrozole—breast cancer	0.000344	0.00469	CcSEcCtD
Amlexanox—Nausea—Letrozole—breast cancer	0.000344	0.00469	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000342	0.00466	CcSEcCtD
Amlexanox—Paraesthesia—Goserelin—breast cancer	0.00034	0.00463	CcSEcCtD
Amlexanox—Pain—Tamoxifen—breast cancer	0.000339	0.00462	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Melphalan—breast cancer	0.000335	0.00456	CcSEcCtD
Amlexanox—Nervous system disorder—Vinorelbine—breast cancer	0.000332	0.00453	CcSEcCtD
Amlexanox—Pain—Melphalan—breast cancer	0.000331	0.00452	CcSEcCtD
Amlexanox—Mouth ulceration—Epirubicin—breast cancer	0.00033	0.0045	CcSEcCtD
Amlexanox—Nausea—Idarubicin—breast cancer	0.000326	0.00445	CcSEcCtD
Amlexanox—Nausea—Raloxifene—breast cancer	0.000326	0.00445	CcSEcCtD
Amlexanox—Pain—Goserelin—breast cancer	0.000323	0.00441	CcSEcCtD
Amlexanox—Nervous system disorder—Thiotepa—breast cancer	0.000317	0.00432	CcSEcCtD
Amlexanox—Mouth ulceration—Doxorubicin—breast cancer	0.000305	0.00416	CcSEcCtD
Amlexanox—Paraesthesia—Vinorelbine—breast cancer	0.000304	0.00415	CcSEcCtD
Amlexanox—Stomatitis—Docetaxel—breast cancer	0.000295	0.00402	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000292	0.00399	CcSEcCtD
Amlexanox—Paraesthesia—Thiotepa—breast cancer	0.00029	0.00396	CcSEcCtD
Amlexanox—Pain—Vinorelbine—breast cancer	0.00029	0.00395	CcSEcCtD
Amlexanox—Stomatitis—Capecitabine—breast cancer	0.000286	0.0039	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Thiotepa—breast cancer	0.000279	0.00381	CcSEcCtD
Amlexanox—Pain—Thiotepa—breast cancer	0.000277	0.00377	CcSEcCtD
Amlexanox—Nervous system disorder—Irinotecan—breast cancer	0.000274	0.00373	CcSEcCtD
Amlexanox—Nervous system disorder—Gemcitabine—breast cancer	0.000267	0.00364	CcSEcCtD
Amlexanox—Nausea—Chlorambucil—breast cancer	0.000264	0.0036	CcSEcCtD
Amlexanox—Nervous system disorder—Fluorouracil—breast cancer	0.000262	0.00358	CcSEcCtD
Amlexanox—Liver function test abnormal—Methotrexate—breast cancer	0.000261	0.00356	CcSEcCtD
Amlexanox—Headache—Vinblastine—breast cancer	0.000255	0.00348	CcSEcCtD
Amlexanox—Paraesthesia—Irinotecan—breast cancer	0.000251	0.00342	CcSEcCtD
Amlexanox—Paraesthesia—Mitoxantrone—breast cancer	0.000251	0.00342	CcSEcCtD
Amlexanox—Headache—Tamoxifen—breast cancer	0.000248	0.00338	CcSEcCtD
Amlexanox—Liver function test abnormal—Epirubicin—breast cancer	0.000245	0.00334	CcSEcCtD
Amlexanox—Paraesthesia—Gemcitabine—breast cancer	0.000244	0.00333	CcSEcCtD
Amlexanox—Nausea—Vinblastine—breast cancer	0.000242	0.0033	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Irinotecan—breast cancer	0.000241	0.00329	CcSEcCtD
Amlexanox—Paraesthesia—Fluorouracil—breast cancer	0.00024	0.00328	CcSEcCtD
Amlexanox—Pain—Mitoxantrone—breast cancer	0.000239	0.00326	CcSEcCtD
Amlexanox—Pain—Irinotecan—breast cancer	0.000239	0.00326	CcSEcCtD
Amlexanox—Headache—Goserelin—breast cancer	0.000237	0.00323	CcSEcCtD
Amlexanox—Nausea—Tamoxifen—breast cancer	0.000235	0.00321	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000235	0.0032	CcSEcCtD
Amlexanox—Pain—Gemcitabine—breast cancer	0.000233	0.00317	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000231	0.00315	CcSEcCtD
Amlexanox—Nausea—Melphalan—breast cancer	0.00023	0.00314	CcSEcCtD
Amlexanox—Pain—Fluorouracil—breast cancer	0.000229	0.00312	CcSEcCtD
Amlexanox—Liver function test abnormal—Doxorubicin—breast cancer	0.000226	0.00309	CcSEcCtD
Amlexanox—Nausea—Goserelin—breast cancer	0.000225	0.00306	CcSEcCtD
Amlexanox—Nervous system disorder—Paclitaxel—breast cancer	0.000223	0.00305	CcSEcCtD
Amlexanox—Stomatitis—Methotrexate—breast cancer	0.000213	0.0029	CcSEcCtD
Amlexanox—Headache—Vinorelbine—breast cancer	0.000212	0.00289	CcSEcCtD
Amlexanox—Paraesthesia—Paclitaxel—breast cancer	0.000205	0.00279	CcSEcCtD
Amlexanox—Headache—Thiotepa—breast cancer	0.000203	0.00276	CcSEcCtD
Amlexanox—Nausea—Vinorelbine—breast cancer	0.000201	0.00274	CcSEcCtD
Amlexanox—Stomatitis—Epirubicin—breast cancer	0.000199	0.00271	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000197	0.00268	CcSEcCtD
Amlexanox—Pain—Paclitaxel—breast cancer	0.000195	0.00266	CcSEcCtD
Amlexanox—Nausea—Thiotepa—breast cancer	0.000192	0.00262	CcSEcCtD
Amlexanox—Nervous system disorder—Docetaxel—breast cancer	0.000189	0.00258	CcSEcCtD
Amlexanox—Stomatitis—Doxorubicin—breast cancer	0.000184	0.00251	CcSEcCtD
Amlexanox—Nervous system disorder—Capecitabine—breast cancer	0.000183	0.0025	CcSEcCtD
Amlexanox—Headache—Mitoxantrone—breast cancer	0.000175	0.00239	CcSEcCtD
Amlexanox—Headache—Irinotecan—breast cancer	0.000175	0.00239	CcSEcCtD
Amlexanox—Paraesthesia—Docetaxel—breast cancer	0.000173	0.00236	CcSEcCtD
Amlexanox—Headache—Gemcitabine—breast cancer	0.00017	0.00232	CcSEcCtD
Amlexanox—Paraesthesia—Capecitabine—breast cancer	0.000168	0.00229	CcSEcCtD
Amlexanox—Headache—Fluorouracil—breast cancer	0.000168	0.00228	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Docetaxel—breast cancer	0.000167	0.00227	CcSEcCtD
Amlexanox—Nausea—Mitoxantrone—breast cancer	0.000166	0.00226	CcSEcCtD
Amlexanox—Nausea—Irinotecan—breast cancer	0.000166	0.00226	CcSEcCtD
Amlexanox—Pain—Docetaxel—breast cancer	0.000165	0.00225	CcSEcCtD
Amlexanox—Nausea—Gemcitabine—breast cancer	0.000162	0.0022	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Capecitabine—breast cancer	0.000161	0.0022	CcSEcCtD
Amlexanox—Pain—Capecitabine—breast cancer	0.00016	0.00218	CcSEcCtD
Amlexanox—Nausea—Fluorouracil—breast cancer	0.000159	0.00217	CcSEcCtD
Amlexanox—Headache—Paclitaxel—breast cancer	0.000143	0.00195	CcSEcCtD
Amlexanox—Nervous system disorder—Methotrexate—breast cancer	0.000136	0.00186	CcSEcCtD
Amlexanox—Nausea—Paclitaxel—breast cancer	0.000135	0.00184	CcSEcCtD
Amlexanox—Nervous system disorder—Epirubicin—breast cancer	0.000128	0.00174	CcSEcCtD
Amlexanox—Paraesthesia—Methotrexate—breast cancer	0.000125	0.0017	CcSEcCtD
Amlexanox—Headache—Docetaxel—breast cancer	0.000121	0.00165	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Methotrexate—breast cancer	0.00012	0.00164	CcSEcCtD
Amlexanox—Pain—Methotrexate—breast cancer	0.000119	0.00162	CcSEcCtD
Amlexanox—Nervous system disorder—Doxorubicin—breast cancer	0.000118	0.00161	CcSEcCtD
Amlexanox—Headache—Capecitabine—breast cancer	0.000117	0.0016	CcSEcCtD
Amlexanox—Paraesthesia—Epirubicin—breast cancer	0.000117	0.00159	CcSEcCtD
Amlexanox—Nausea—Docetaxel—breast cancer	0.000115	0.00156	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Epirubicin—breast cancer	0.000112	0.00153	CcSEcCtD
Amlexanox—Pain—Epirubicin—breast cancer	0.000111	0.00152	CcSEcCtD
Amlexanox—Nausea—Capecitabine—breast cancer	0.000111	0.00151	CcSEcCtD
Amlexanox—Paraesthesia—Doxorubicin—breast cancer	0.000108	0.00148	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000104	0.00142	CcSEcCtD
Amlexanox—Pain—Doxorubicin—breast cancer	0.000103	0.0014	CcSEcCtD
Amlexanox—Headache—Methotrexate—breast cancer	8.72e-05	0.00119	CcSEcCtD
Amlexanox—Nausea—Methotrexate—breast cancer	8.27e-05	0.00113	CcSEcCtD
Amlexanox—Headache—Epirubicin—breast cancer	8.16e-05	0.00111	CcSEcCtD
Amlexanox—Nausea—Epirubicin—breast cancer	7.74e-05	0.00105	CcSEcCtD
Amlexanox—Headache—Doxorubicin—breast cancer	7.55e-05	0.00103	CcSEcCtD
Amlexanox—Nausea—Doxorubicin—breast cancer	7.16e-05	0.000976	CcSEcCtD
Amlexanox—FGF1—Immune System—IL1B—breast cancer	5.14e-06	2.97e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CD4—breast cancer	5.14e-06	2.97e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—BRAF—breast cancer	5.13e-06	2.96e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL2—breast cancer	5.12e-06	2.96e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ERBB2—breast cancer	5.11e-06	2.95e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KDR—breast cancer	5.11e-06	2.95e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTGS2—breast cancer	5.1e-06	2.95e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—APC—breast cancer	5.05e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CG—breast cancer	5.05e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KIT—breast cancer	5.05e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MTOR—breast cancer	5.04e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CB—breast cancer	5.04e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CD—breast cancer	5.04e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF1—breast cancer	5e-06	2.88e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT2—breast cancer	4.99e-06	2.88e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—PIK3CA—breast cancer	4.99e-06	2.88e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGF—breast cancer	4.99e-06	2.88e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SERPINE1—breast cancer	4.98e-06	2.88e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—JUN—breast cancer	4.98e-06	2.88e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ESR1—breast cancer	4.98e-06	2.87e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—EGFR—breast cancer	4.97e-06	2.87e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CTNNB1—breast cancer	4.95e-06	2.86e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—KRAS—breast cancer	4.93e-06	2.85e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FN1—breast cancer	4.92e-06	2.84e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—AKT1—breast cancer	4.86e-06	2.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NFKBIA—breast cancer	4.86e-06	2.81e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CXCL8—breast cancer	4.85e-06	2.8e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—MAPK3—breast cancer	4.83e-06	2.79e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1B—breast cancer	4.83e-06	2.79e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDKN1A—breast cancer	4.83e-06	2.79e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PTEN—breast cancer	4.82e-06	2.78e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HRAS—breast cancer	4.82e-06	2.78e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOTCH1—breast cancer	4.81e-06	2.78e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—PIK3CA—breast cancer	4.8e-06	2.77e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CD—breast cancer	4.8e-06	2.77e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—AKT1—breast cancer	4.77e-06	2.75e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NOS3—breast cancer	4.76e-06	2.75e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—PIK3CA—breast cancer	4.75e-06	2.74e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—BRAF—breast cancer	4.74e-06	2.74e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SERPINE1—breast cancer	4.74e-06	2.74e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1B—breast cancer	4.73e-06	2.73e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MAPK8—breast cancer	4.72e-06	2.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KIT—breast cancer	4.71e-06	2.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—APC—breast cancer	4.71e-06	2.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CG—breast cancer	4.71e-06	2.72e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—KRAS—breast cancer	4.7e-06	2.71e-05	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—AKT1—breast cancer	4.68e-06	2.7e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGF—breast cancer	4.65e-06	2.69e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TP53—breast cancer	4.64e-06	2.68e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CASP3—breast cancer	4.64e-06	2.68e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL2—breast cancer	4.63e-06	2.68e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF1—breast cancer	4.62e-06	2.67e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT2—breast cancer	4.62e-06	2.67e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—IL6—breast cancer	4.61e-06	2.66e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—EGFR—breast cancer	4.6e-06	2.66e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—AKT1—breast cancer	4.58e-06	2.64e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CTNNB1—breast cancer	4.57e-06	2.64e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—PIK3CA—breast cancer	4.53e-06	2.62e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NOS3—breast cancer	4.53e-06	2.61e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CCND1—breast cancer	4.52e-06	2.61e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MDM2—breast cancer	4.51e-06	2.61e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—JUN—breast cancer	4.51e-06	2.6e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—RAF1—breast cancer	4.5e-06	2.6e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—RELA—breast cancer	4.48e-06	2.59e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CTNNB1—breast cancer	4.47e-06	2.58e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—SRC—breast cancer	4.47e-06	2.58e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1A—breast cancer	4.46e-06	2.58e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTEN—breast cancer	4.45e-06	2.57e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ERBB2—breast cancer	4.45e-06	2.57e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HRAS—breast cancer	4.44e-06	2.56e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CD—breast cancer	4.44e-06	2.56e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—BRAF—breast cancer	4.42e-06	2.55e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—PIK3CA—breast cancer	4.4e-06	2.54e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MTOR—breast cancer	4.39e-06	2.54e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CB—breast cancer	4.39e-06	2.54e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SERPINE1—breast cancer	4.39e-06	2.53e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MMP9—breast cancer	4.39e-06	2.53e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1A—breast cancer	4.37e-06	2.52e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PTEN—breast cancer	4.36e-06	2.52e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—KRAS—breast cancer	4.34e-06	2.51e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—PIK3CA—breast cancer	4.31e-06	2.49e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—STAT3—breast cancer	4.31e-06	2.49e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF1—breast cancer	4.31e-06	2.49e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT2—breast cancer	4.31e-06	2.49e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MDM2—breast cancer	4.3e-06	2.48e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—RAF1—breast cancer	4.28e-06	2.47e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MAPK8—breast cancer	4.26e-06	2.46e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—RELA—breast cancer	4.26e-06	2.46e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—AKT1—breast cancer	4.25e-06	2.46e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—IL6—breast cancer	4.25e-06	2.45e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ERBB2—breast cancer	4.24e-06	2.45e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CXCL8—breast cancer	4.22e-06	2.44e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HRAS—breast cancer	4.19e-06	2.42e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NOS3—breast cancer	4.19e-06	2.42e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MTOR—breast cancer	4.18e-06	2.41e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CB—breast cancer	4.18e-06	2.41e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CD—breast cancer	4.14e-06	2.39e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—SRC—breast cancer	4.13e-06	2.38e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1B—breast cancer	4.12e-06	2.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MAPK3—breast cancer	4.12e-06	2.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SERPINE1—breast cancer	4.09e-06	2.36e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—AKT1—breast cancer	4.08e-06	2.35e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SRC—breast cancer	4.04e-06	2.33e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CASP3—breast cancer	4.04e-06	2.33e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL2—breast cancer	4.03e-06	2.33e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CXCL8—breast cancer	4.02e-06	2.32e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—IL6—breast cancer	4.01e-06	2.32e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—PIK3CA—breast cancer	3.99e-06	2.3e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HRAS—breast cancer	3.99e-06	2.3e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—STAT3—breast cancer	3.98e-06	2.3e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MDM2—breast cancer	3.98e-06	2.3e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—RAF1—breast cancer	3.96e-06	2.29e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—RELA—breast cancer	3.94e-06	2.28e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—VEGFA—breast cancer	3.94e-06	2.27e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCND1—breast cancer	3.93e-06	2.27e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—JUN—breast cancer	3.92e-06	2.27e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1B—breast cancer	3.92e-06	2.27e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—AKT1—breast cancer	3.92e-06	2.26e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ERBB2—breast cancer	3.92e-06	2.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EGFR—breast cancer	3.92e-06	2.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOS3—breast cancer	3.91e-06	2.26e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—STAT3—breast cancer	3.9e-06	2.25e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CTNNB1—breast cancer	3.89e-06	2.25e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—AKT1—breast cancer	3.88e-06	2.24e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MTOR—breast cancer	3.87e-06	2.23e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CB—breast cancer	3.87e-06	2.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CASP3—breast cancer	3.84e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL2—breast cancer	3.84e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—IL6—breast cancer	3.82e-06	2.21e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MMP9—breast cancer	3.82e-06	2.2e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1A—breast cancer	3.8e-06	2.2e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MAPK3—breast cancer	3.8e-06	2.2e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PTEN—breast cancer	3.8e-06	2.19e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCND1—breast cancer	3.74e-06	2.16e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—JUN—breast cancer	3.73e-06	2.16e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MAPK3—breast cancer	3.72e-06	2.15e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CXCL8—breast cancer	3.72e-06	2.15e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAPK8—breast cancer	3.71e-06	2.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MDM2—breast cancer	3.71e-06	2.14e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CTNNB1—breast cancer	3.71e-06	2.14e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—AKT1—breast cancer	3.7e-06	2.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—KRAS—breast cancer	3.7e-06	2.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MYC—breast cancer	3.7e-06	2.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RAF1—breast cancer	3.69e-06	2.13e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HRAS—breast cancer	3.69e-06	2.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFB1—breast cancer	3.69e-06	2.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—RELA—breast cancer	3.68e-06	2.12e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ERBB2—breast cancer	3.65e-06	2.11e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MMP9—breast cancer	3.63e-06	2.1e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1B—breast cancer	3.63e-06	2.1e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MYC—breast cancer	3.62e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1A—breast cancer	3.62e-06	2.09e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—EGFR—breast cancer	3.62e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFB1—breast cancer	3.61e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PTEN—breast cancer	3.61e-06	2.09e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CB—breast cancer	3.61e-06	2.08e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MTOR—breast cancer	3.61e-06	2.08e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—AKT1—breast cancer	3.59e-06	2.07e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CASP3—breast cancer	3.56e-06	2.05e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL2—breast cancer	3.55e-06	2.05e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EGFR—breast cancer	3.54e-06	2.05e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—IL6—breast cancer	3.53e-06	2.04e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAPK8—breast cancer	3.53e-06	2.04e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—AKT1—breast cancer	3.52e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SRC—breast cancer	3.52e-06	2.03e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CXCL8—breast cancer	3.47e-06	2e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCND1—breast cancer	3.46e-06	2e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—JUN—breast cancer	3.46e-06	2e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CTNNB1—breast cancer	3.43e-06	1.98e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—VEGFA—breast cancer	3.43e-06	1.98e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—KRAS—breast cancer	3.42e-06	1.97e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PIK3CA—breast cancer	3.4e-06	1.96e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—STAT3—breast cancer	3.39e-06	1.96e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1B—breast cancer	3.38e-06	1.95e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MMP9—breast cancer	3.36e-06	1.94e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1A—breast cancer	3.35e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SRC—breast cancer	3.35e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—KRAS—breast cancer	3.35e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PTEN—breast cancer	3.34e-06	1.93e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CASP3—breast cancer	3.32e-06	1.92e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL2—breast cancer	3.31e-06	1.91e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAPK8—breast cancer	3.27e-06	1.89e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—VEGFA—breast cancer	3.26e-06	1.88e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—AKT1—breast cancer	3.26e-06	1.88e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAPK3—breast cancer	3.24e-06	1.87e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—STAT3—breast cancer	3.23e-06	1.87e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCND1—breast cancer	3.23e-06	1.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—JUN—breast cancer	3.22e-06	1.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CTNNB1—breast cancer	3.2e-06	1.85e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MYC—breast cancer	3.15e-06	1.82e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFB1—breast cancer	3.15e-06	1.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HRAS—breast cancer	3.15e-06	1.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CA—breast cancer	3.14e-06	1.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MMP9—breast cancer	3.13e-06	1.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1A—breast cancer	3.12e-06	1.8e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PTEN—breast cancer	3.12e-06	1.8e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SRC—breast cancer	3.1e-06	1.79e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAPK3—breast cancer	3.09e-06	1.78e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EGFR—breast cancer	3.08e-06	1.78e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CA—breast cancer	3.08e-06	1.78e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAPK8—breast cancer	3.05e-06	1.76e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—VEGFA—breast cancer	3.02e-06	1.74e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL6—breast cancer	3.01e-06	1.74e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MYC—breast cancer	3e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFB1—breast cancer	2.99e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—STAT3—breast cancer	2.99e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TP53—breast cancer	2.98e-06	1.72e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EGFR—breast cancer	2.94e-06	1.7e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—KRAS—breast cancer	2.91e-06	1.68e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—HRAS—breast cancer	2.9e-06	1.68e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SRC—breast cancer	2.89e-06	1.67e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAPK3—breast cancer	2.86e-06	1.65e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HRAS—breast cancer	2.85e-06	1.64e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—VEGFA—breast cancer	2.81e-06	1.63e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—STAT3—breast cancer	2.79e-06	1.61e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—IL6—breast cancer	2.78e-06	1.61e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT1—breast cancer	2.78e-06	1.6e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MYC—breast cancer	2.78e-06	1.6e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—KRAS—breast cancer	2.77e-06	1.6e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFB1—breast cancer	2.77e-06	1.6e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL6—breast cancer	2.72e-06	1.57e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGFR—breast cancer	2.72e-06	1.57e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CA—breast cancer	2.68e-06	1.55e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAPK3—breast cancer	2.66e-06	1.54e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TP53—breast cancer	2.59e-06	1.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MYC—breast cancer	2.59e-06	1.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFB1—breast cancer	2.58e-06	1.49e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KRAS—breast cancer	2.57e-06	1.48e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT1—breast cancer	2.56e-06	1.48e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CA—breast cancer	2.55e-06	1.47e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGFR—breast cancer	2.53e-06	1.46e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT1—breast cancer	2.51e-06	1.45e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HRAS—breast cancer	2.48e-06	1.43e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TP53—breast cancer	2.47e-06	1.42e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KRAS—breast cancer	2.39e-06	1.38e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL6—breast cancer	2.37e-06	1.37e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CA—breast cancer	2.36e-06	1.36e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HRAS—breast cancer	2.36e-06	1.36e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TP53—breast cancer	2.28e-06	1.32e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6—breast cancer	2.26e-06	1.3e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CA—breast cancer	2.2e-06	1.27e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT1—breast cancer	2.19e-06	1.26e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HRAS—breast cancer	2.18e-06	1.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TP53—breast cancer	2.13e-06	1.23e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6—breast cancer	2.09e-06	1.21e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT1—breast cancer	2.08e-06	1.2e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HRAS—breast cancer	2.03e-06	1.17e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6—breast cancer	1.95e-06	1.12e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT1—breast cancer	1.93e-06	1.11e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT1—breast cancer	1.8e-06	1.04e-05	CbGpPWpGaD
